ASH 2024 | Phase Ib study of IO-202 with azacitidine for HMA-naive CMML
Gabriel Mannis, MD, Stanford University School of Medicine, Stanford, CA, shares findings from a Phase Ib study evaluating IO-202, a novel anti-LILRB4 antibody, with azacitidine for patients with hypomethylating agent (HMA)-naive chronic myelomonocytic leukemia (CMML). Of the 18 efficacy evaluable patients, the overall response rate (ORR) was 66.7%, with almost 40% of patients proceeding to transplant. Responses were seen across all subsets of patients, and these findings support future studies on this agent. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
